With conditional approval of the drug Ataluren for Duchenne muscular dystrophy by the European Union, patients hope for a path to a cure!
A drug to treat Duchenne muscular dystrophy, once dismissed by the FDA as "premature," has promising new trial data to move it forward.
History was made when a left ventricular assist device (LVAD) was implanted in a muscular dystrophy patient. Here's why!
A new drug for Duchenne muscular dystrophy improves patients' ability to walk through proteins vital to muscle growth and health.